Imipenem
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1985
- First approval year
- 1985
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Imipenem
- Molecular weight
- 317.37
- Structure (SMILES)
- C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O
- imipenem component of primaxin
- Imipenem component of primaxin
- imipenem component of recarbrio
- Imipenem component of recarbrio
- h2o
- H2O
- imipemide
- Imipemide
- imipenem
- Imipenem
- IMIPENEM [MART.]
- IMIPENEM [ORANGE BOOK]
- IMIPENEM [USAN]
- IMIPENEM [USP MONOGRAPH]
- IMIPENEM [VANDF]
- imipenem hydrate
- Imipenem hydrate
- IMIPENEM HYDRATE [JAN]
- imipenem hydrate jan
- imipenem mart
- imipenem monohydrate
- Imipenem monohydrate
- Imipenem monohydrate (h2o)
- IMIPENEM MONOHYDRATE [EP MONOGRAPH]
- IMIPENEM MONOHYDRATE [MI]
- IMIPENEM MONOHYDRATE [USP-RS]
- Imipenem monohydrate [WHO-DD]
- imipenem monohydrate ep monograph
- imipenem monohydrate h2o
And 15 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL43708
- InChIKey
- GSOSVVULSKVSLQ-JJVRHELESA-N
- FDA ingredient codes (UNII)
- 71OTZ9ZE0A
- 64221-86-9
- 74431-23-5
- 5282372
- 168341515
- 5690
- 2184135
- Applicant
- MERCK
- Approval date
- 26 Nov 1985
- Application number
- NDA050587
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- imipenem
- Type
- Synthetic organic
- Drug name stem
- -penem
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P02918
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P02919
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P08506
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AD65
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AD68
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AEB2
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P24228
Open Targets mechanisms
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB
- Protein identifier
- P02918|P02919|P08506|P0AD65|P0AD68|P0AEB2|P24228
- Organism
- Escherichia coli (strain K12)
- Condition
- Endocarditis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000465
- Subject identifier
- D004696
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Intraabdominal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D059413
- Condition
- Bacterial Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001642
- Subject identifier
- D019337
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Lung Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Pyelonephritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001141
- Subject identifier
- D011704
- Condition
- Pneumonia, Bacterial
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001272
- Subject identifier
- D018410
- Condition
- Enterobacteriaceae Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001313
- Subject identifier
- D004756
- Condition
- Pneumonia, Ventilator-Associated
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001865
- Subject identifier
- D053717
- Condition
- Sepsis
- Highest recorded phase
- 4
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0044881
- Subject identifier
- D019337
- Condition identifier
- EFO_0000465
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0001642
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0006834
- Condition identifier
- EFO_1001272
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001313
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001865
- Highest recorded phase
- 3
- Condition identifier
- HP_0002783
- Condition identifier
- HP_0100523
- Highest recorded phase
- 3
- Condition identifier
- HP_0100806
- Condition identifier
- HP_0100806
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003529
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004652
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005025
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005229
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006939
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021678
And 2 more, listed on the interactive page.
- Event
- acinetobacter infection
- Reports
- 8
- Reporting signal score
- 24.3753
- Event
- acute generalised exanthematous pustulosis
- Reports
- 25
- Reporting signal score
- 42.1407
- Event
- agranulocytosis
- Reports
- 28
- Reporting signal score
- 31.1487
- Event
- clostridium difficile colitis
- Reports
- 25
- Reporting signal score
- 43.2231
- Event
- clostridium test positive
- Reports
- 11
- Reporting signal score
- 29.703
- Event
- convulsion
- Reports
- 137
- Reporting signal score
- 224.791
- Event
- cytolytic hepatitis
- Reports
- 14
- Reporting signal score
- 24.2895
- Event
- deafness
- Reports
- 25
- Reporting signal score
- 31.9375
- Event
- dermatitis exfoliative
- Reports
- 21
- Reporting signal score
- 39.078
- Event
- dizziness
- Reports
- 11
- Reporting signal score
- 27.9537
- Event
- drug rash with eosinophilia and systemic symptoms
- Reports
- 21
- Reporting signal score
- 44.896
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 37
- Reporting signal score
- 40.0061
- Event
- drug resistance
- Reports
- 62
- Reporting signal score
- 106.707
- Event
- electrocardiogram qt prolonged
- Reports
- 54
- Reporting signal score
- 62.9446
- Event
- enterococcus test positive
- Reports
- 12
- Reporting signal score
- 44.8451
- Event
- eosinophilia
- Reports
- 62
- Reporting signal score
- 121.16
- Event
- epilepsy
- Reports
- 38
- Reporting signal score
- 43.9806
- Event
- fall
- Reports
- 4
- Reporting signal score
- 27.6891
- Event
- fatigue
- Reports
- 11
- Reporting signal score
- 49.406
- Event
- fungaemia
- Reports
- 15
- Reporting signal score
- 49.959
- Event
- geotrichum infection
- Reports
- 6
- Reporting signal score
- 27.1308
- Event
- grand mal convulsion
- Reports
- 28
- Reporting signal score
- 46.8687
- Event
- granulomatosis with polyangiitis
- Reports
- 11
- Reporting signal score
- 35.6771
- Event
- headache
- Reports
- 12
- Reporting signal score
- 35.2199
- Event
- hepatic cytolysis
- Reports
- 15
- Reporting signal score
- 33.0684
And 18 more, listed on the interactive page.
- NCT00080496
- NCT00707239
- NCT02493764
- NCT05204563
- NCT00236834
- NCT00445094
- NCT01379157
- NCT03177720
- NCT01381549
- NCT01506271
- NCT01659866
- NCT01721408
- NCT02971423
- NCT00589693
- NCT00690378
- NCT01505634
- NCT02321800
- NCT02474706
- NCT03543436
- NCT05204368
- NCT06059846
- NCT02099240
- NCT02452047
- NCT04787562
- NCT04801043
And 8 more, listed on the interactive page.
- Dose
- 1.25 grams (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg)
- Route
- Intravenous
- How often
- Every 6 hours
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 4
- Polar surface area
- 113.72
- Calculated partition coefficient (ALogP)
- -0.18
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 21
- Molecular formula
- C12H19N3O5S
- Monoisotopic mass
- 317.10454189
- Natural product
- No
- 0006-3516
- 63323-322
- 63323-349
- Recorded assays
- 138
- Active assays
- 1
Active assay types
- Other
Related records
Trials (65)
- A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)
- A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
- A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
- A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization
- A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
- A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
- Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy
- Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
- Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
- Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
- Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
- Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia
- Complicated Skin and Skin Structure Infections
- Effect of Aerosolised Colistin in Ventilator Associated Pneumonia
Approved for (3)
- Endocarditis
- Pneumonia
- Urinary tract infection
In development for (7)
- Bacterial infectious disease Phase 3
- Bacterial pneumonia Phase 3
- Hematopoietic and lymphoid cell neoplasm Phase 2
- Lung disorder Phase 2
- Lymphoid neoplasm Phase 2
- Osteomyelitis Early phase 1
- Pyelonephritis Phase 3